Headlines about Argos Therapeutics (NASDAQ:ARGS) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Argos Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.5608756144645 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Hot Stock of the Day – Argos Therapeutics Inc (NASDAQ: ARGS) – Alpha Beta Stock (alphabetastock.com)
- Argos Therapeutics, Inc. (ARGS) Shows Effort to Maintain Active Position in Short-Range Commitments – Stock News Stop (stockmarketstop.com)
- Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy (thenewsreports.com)
- Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy (finance.yahoo.com)
- A Daytrader’s Guide To Fear (finance.yahoo.com)
Separately, ValuEngine upgraded Argos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating and three have issued a hold rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $24.00.
TRADEMARK VIOLATION WARNING: This report was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.chaffeybreeze.com/2018/02/19/argos-therapeutics-args-getting-somewhat-favorable-news-coverage-analysis-finds.html.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.